Skip to main content
. 2020 Jul 1;9(16):5827–5838. doi: 10.1002/cam4.3259

FIGURE 2.

FIGURE 2

Function of anti‐CD19 and anti‐CD20 CAR‐T cells in R/R DLBCL. (A, B) The median PFS and OS of 21 patients are shown. (C) The response duration and non‐relapse mortality (NRM) (D) of 17 patients with response are shown. The survival fractions were calculated by the Kaplan‐Meier method, and the (green) lines indicate censored patients. (E) The clinical responds and survival condition of anti‐CD19 combined with anti‐CD20 CAR‐T cells therapy